+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 14Years +
All Genders
ID06611839

Study of Venetoclax, Ivosidenib, and Azacitidine Treatment in Adults 14 Years and Older With Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-05-13

23

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination treatment for adult patients with newly diagnosed acute myeloid leukemia AML who have IDH1 mutations. This study focuses on patients eligible for chemotherapy and aims to assess the long-term effectiveness of a triple-drug regimen including venetoclax, ivosidenib, and azacitidine. IDH1 mutations affect gene expression and cell differentiation, and this approach builds on previous findings showing promising remission and survival rates in similar patient groups. The treatment begins with an induction phase using venetoclax, ivosidenib, and azacitidine. Venetoclax dosing increases from 100 mg on day 1 to 800 mg from day 4 to 14, ivosidenib is given at 500 mg daily for 28 days, and azacitidine is administered at 75 mgm2 daily for 7 days. Following induction, patients receive consolidation therapy with intermediate-dose cytarabine for three courses, with added ivosidenib if residual disease is detected. Maintenance treatment includes six courses of azacitidine, venetoclax, and ivosidenib. Participants will be monitored through various assessments including remission rates and molecular response measured by flow cytometry and PCR after induction therapy. Safety and dosage limits of the drug combination will be evaluated within three months of treatment start. Long-term outcomes like event-free survival, overall survival, relapse-free survival, and mortality at 30 and 60 days will be tracked for up to two years. Informed consent is required, and the study spans from screening through extended follow-up to evaluate treatment effects thoroughly.

CONDITIONS

Brief Title

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Research Team

H

Hui Wei, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here